PaySign, Inc. (PAYS)

PaySign's stock performance has been influenced by quarterly earnings reports and market sentiment. In Q2 2025, PaySign reported record revenue with significant growth in the patient affordability business, despite a revenue decline in the plasma industry segment. In Q3 2025, the company announced an EPS of $0.04, beating estimates, and quarterly revenue of $21.60 million, also exceeding expectations. The stock experienced a pullback in October 2025, but as of December 24, 2025, the share price had increased by 61.45% from the previous year. Analysts maintained a 'Strong Buy' consensus rating with an average price target of $8.06 as of November 13, 2025.

Demand seasonality for PaySign's products and services varies across segments. The pharma patient affordability segment experiences seasonally strong processed claim volume, with high demand expected for co-payment cards and expanded patient affordability programs. The plasma donor compensation segment faces volatility due to industry partners' location changes. The general prepaid card market in the US is strong and expanding.

PaySign, Inc. is a Nevada-based fintech company specializing in prepaid card programs and integrated payment processing services, operating primarily within the Diversified Financials sector, with a focus on Transaction and Payment Processing Services and Healthcare Fintech industries. The company offers prepaid card programs, digital banking services like PaySign Premier, integrated payment processing through its PaySign platform, patient affordability offerings including pharmacy-based voucher and copay programs, and per diem/corporate expense payment solutions.

PaySign, Inc. is headquartered in Henderson, Nevada, with its principal target markets for processing services located in the United States and Mexico. The company has recently expanded with a new patient service support center in Henderson, Nevada.

PaySign's brand reputation has been positively influenced by its strong performance and strategic advancements, particularly in healthcare fintech. The company is recognized for its technological edge and strategic infrastructure investments. The significant growth in its patient affordability business and the acquisition of Gamma Innovation LLC have also enhanced its reputation. Challenges in the plasma business have been overshadowed by the company's strategic growth and innovation.

PaySign, Inc. has a significant portion of its shares held by institutional and individual owners. Institutional shareholders own 44.59% of the company, with major holders including Topline Capital Management, LLC, BlackRock, Inc., and Vanguard Group Inc. Insiders own 99.45% of PaySign, with individual insiders holding approximately 38% of the company's shares. Mark Newcomer, the CEO, is the largest individual shareholder. Insiders have purchased shares, but have sold more shares than purchased in the last 24 months.